Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.
Peshin, R O'Neill, L Browne, P O'Connell, P Kearns, G
Peshin, R
O'Neill, L
Browne, P
O'Connell, P
Kearns, G
Advisors
Editors
Other Contributors
Date
2009-06
Date Submitted
Keywords
Other Subjects
Subject Mesh
Anti-Inflammatory Agents
Antineoplastic Agents, Alkylating
Cyclophosphamide
Humans
Infusions, Intravenous
Lung Diseases, Interstitial
Male
Middle Aged
Prednisolone
Scleroderma, Systemic
Antineoplastic Agents, Alkylating
Cyclophosphamide
Humans
Infusions, Intravenous
Lung Diseases, Interstitial
Male
Middle Aged
Prednisolone
Scleroderma, Systemic
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Interstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc). There are currently no recommended guidelines for management of these patients. This is probably due to the rarity of this condition, as well as clinical trials with only a small number of cases. There are published case report and case series along with the two main trials, viz. Scleroderma Lung Study and the Fibrosing Alveolitis Study, but again, there is no consensus on treatment protocols. In this report, we present a case of aggressive interstitial lung disease in a patient with SSc, which improved dramatically on treatment with intra-venous cyclophosphamide and high dose prednisolone therapy.
Language
en
ISSN
1434-9949
eISSN
ISBN
DOI
10.1007/s10067-009-1098-y
PMID
19194736